Anne Wojcicki interviewed at Web 2.0 Summit 2011
summary
Company 23andMe launched five years ago offering 500,000 markers for $1,000 and now ships exome sequencing that yields 50 million data points for roughly the same price, aiming to link genetics to drug response and disease. A community of about 600 engaged saroma patients supplies surveys plus genomic data, enabling large-scale association work. Data sharing balances customer privacy with open science—research appears in PLoS and selective APIs and collaborations with academics and pharma support commercialization and downstream treatments.
AI-written summary · about
related talks
18mWho am I, and where do I come from?
17mBig data in personalized medicine
28mBiological Discovery and Consumer Genomics Databases Activate Latent Privacy Risk in...
20mTranslating a Trillion Pointo Diseases of Data into Therapies
14mBig data, AI, the genome, and everything
01h 11mGlobal Perspectives of Regulating Genetic Data in Scientific Research: Beyond Privacy?
12mHow data science can make your genome actionable
16mThe Secret Life of Data - Part 3